Ask AI

The APP Advantage: Optimizing BCMA- and GPRC5D-Directed Bispecific Antibody Care in Multiple Myeloma

Video
This activity is available for 1.00 CME/CE credit(s).

Released: November 03, 2026

Expiration: May 02, 2027

See Activity Collection

Enhance your ability to apply current and emerging evidence on BCMA- and GPRC5D-directed bispecific antibody strategies to improve your care for patients with relapsed/refractory multiple myeloma through this certified on-demand webcast. Topics covered include differentiation of BCMA- and GPRC5D-directed agents, step-up dosing and REMS workflows, infection prevention, CRS/ICANS triage, GPRC5D-specific supportive care, patient/caregiver counseling, and more.

BCMA and GPRC5D BsAbs in MM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Based on the MajesTEC-3 trial and FDA approval, which of the following patients is eligible for the combination of teclistamab and daratumumab?

How confident are you in your answer?
4.

Case: Patient With R/R MM



  • 87-yr-old woman with relapsed/refractory kappa free light chain multiple myeloma

  • Lives between US and Virgin Islands with family support

  • Treatment history: 11 prior lines of therapy with regimens including bortezomib, thalidomide/lenalidomide/pomalidomide, daratumumab-based regimens (DPd, DKd, Dcyd), and isatuximab

  • On progression, she and her oncologist decide to initiate therapy with a bispecific antibody 

In counseling your patient and her husband, which of the following bispecific antibodies would you explain can be administered every 2 wk immediately after completing step-up dosing?

How confident are you in your answer?
5.

Which of the following adverse events occurs more frequently with GPRC5D-targeted therapy compared with BCMA-targeted therapy in multiple myeloma?

How confident are you in your answer?